There is a warning that follows this medication around, and most people run into it somewhere between the doctor's office and the pharmacy counter. It usually arrives as some version of "once you start it, you can never stop." That claim is close enough to true that it deserves a real explanation rather than a pat on the hand, and it is also incomplete enough that it frightens people away from a drug that might be a good fit for them.
Prolia is the brand name for a medication called denosumab. It is given as a single injection under the skin, once every six months. It is a genuinely effective treatment, and it is also the one where stopping without a plan carries the clearest danger. Both of those things are true at the same time, and I do not think anyone can make a good decision about this drug while holding only one of them.
How It Works, and Why That Explains the Rest
Your skeleton is constantly being taken apart and rebuilt. The cells that do the taking apart are called osteoclasts, and they get switched on by a signaling protein with the unhelpful name RANKL. Denosumab is an antibody that grabs onto RANKL before it can deliver its message. Fewer osteoclasts get made, the ones already there become less active, and the rate at which your bone is broken down drops sharply. Medications that work this way are called antiresorptives, which simply means they slow down the breakdown side of the equation.
Here is the part that matters most. Bisphosphonates, the drug family that includes alendronate and zoledronic acid, bind chemically into the bone mineral itself and stay there. When you stop taking one, the drug already sitting in your skeleton keeps working for months or even years afterward. That lingering effect is the reason a bisphosphonate "drug holiday" is a legitimate option for some people.
Denosumab never becomes part of your bone. It circulates in your bloodstream, does its job, and then clears out of your system. One dose holds for roughly six months. When the drug is gone, the RANKL signal comes back, and for a while it comes back louder than it was before you ever started treatment (European Calcified Tissue Society position statement, Bone, 2017). Nearly everything unusual about how this medication has to be managed traces back to that single difference.
What the Research Shows It Can Do
The evidence here is strong, and I would rather give you the actual numbers than a string of adjectives.
The pivotal trial, known as FREEDOM, enrolled 7,808 postmenopausal women with osteoporosis and followed them for three years on either denosumab or a placebo (Cummings and colleagues, New England Journal of Medicine, 2009). Over those three years, according to the FDA prescribing information:
- Spine fractures. 7.2 out of every 100 women on placebo had a new spine fracture, compared with 2.3 out of 100 on denosumab. That works out to a 68% reduction, or roughly five fractures prevented for every hundred women treated.
- Hip fractures. 1.2 out of 100 on placebo, compared with 0.7 out of 100 on denosumab.
- All other fractures. 8.0 out of 100 versus 6.5 out of 100, a 20% reduction.
- Bone density. After three years, the women on denosumab had 8.8% more bone at the spine and 6.4% more at the hip than the placebo group.
I give you both the percentage reduction and the plain head count on purpose. A 68% reduction sounds enormous, and it genuinely is good news, but it is easier to think clearly when you also know it means about five fractures avoided per hundred women over three years.
One caution about all of these figures. FREEDOM compared denosumab against a placebo, not against another osteoporosis drug. So if you set the percentages in this post next to the percentages in my post on bisphosphonates, you are not looking at a head-to-head contest. Trials that put these medications directly against each other and measure fractures are scarce, which is a good part of why expert groups still disagree about which one belongs first.
The long-term picture is unusual in a good way. Women who stayed on denosumab for a full ten years kept gaining bone density the entire time, finishing 21.7% above where they started at the spine and 9.2% higher at the hip, with no sign of leveling off. Fracture rates stayed low throughout the decade, and serious side effects did not climb as the years went on (Bone and colleagues, Lancet Diabetes & Endocrinology, 2017). Most osteoporosis medications deliver most of their density gain early and then flatten out. This one kept going.
What Getting It Actually Looks Like
The dose is 60 mg, given as one injection just under the skin of the upper arm, the thigh, or the abdomen, once every six months. A nurse or another health professional gives it to you, so this is not a medication you take home and inject yourself. The label also asks you to take 1,000 mg of calcium and at least 400 IU of vitamin D every day while you are on it, because the drug pulls hard on the calcium circulating in your blood and you do not want that level dropping.
In daily life this is one of the easiest osteoporosis medications to live with. Two appointments a year, no fasting beforehand, and none of the sitting upright for half an hour that oral bisphosphonates require. For people who could not tolerate a pill, or who never quite managed to take one correctly, that simplicity is a real advantage and not a small one.
The Caveat That Changes Everything
Now the part I would want a member of my own family to hear clearly.
When denosumab is stopped, bone loss does not simply pick back up at its old pace. It speeds past it. The FDA label spells out the sequence. The rate of bone breakdown climbs above where it was before you ever started treatment by about nine months after the last dose, and the bone density you worked to gain returns to where it began within roughly eighteen months. New spine fractures have shown up as early as seven months after a dose was missed, with nineteen months being the average timing.
In the trial data, 6 out of every 100 women who stopped denosumab and stayed under observation went on to have a new spine fracture. When researchers looked at everyone who stopped, the spine fracture rate rose from about 1 fracture per 100 women per year while on treatment to about 7 per 100 women per year after stopping, which is essentially the same rate seen in women who had never been treated at all (Cummings and colleagues, Journal of Bone and Mineral Research, 2018).
The figure that concerns me most is a different one. Among the women who did fracture after stopping, 60.7% broke more than one vertebra. One compression fracture is hard enough. Several of them at once, in a short window, is a different category of event, and it can permanently change a person's height, posture, and level of daily pain. Women who had already had a spine fracture, either before treatment or during it, were about four times more likely to end up in that group.
I will be straightforward with you about something. This particular risk is not abstract for me. I know first-hand what multiple spine fractures do to a person, and that experience is a good part of why I ended up writing a book about this disease instead of keeping quiet about it.
Which is what makes the next part worth saying out loud. Prolia is still on my own list. I am partway through a two-year course of an anabolic medication, and when it ends I will need an antiresorptive behind it to hold onto the bone I gained, because those gains do not stay put on their own. Denosumab is one of the options I expect to weigh with my own doctor, in the same risk and benefit conversation I keep encouraging you to have with yours. Understanding the rebound has not talked me out of it. It has shown me what I would want in place before a first injection.
The practical implication is not that Prolia is a dangerous drug. It is that Prolia depends on continuity of care, and continuity of care turns out to be fragile. People move and insurance changes. A dose gets pushed back because of dental work or an appointment that never got rebooked. Reviews of this rebound effect find that fractures cluster between six and eighteen months after the last injection, with a middle point around ten months, and that even a four-month delay in a scheduled dose measurably raises spine fracture risk (Anastasilakis and colleagues, Journal of Clinical Medicine, 2021).
Because of all this, the guidance is remarkably consistent across sources. The FDA label states plainly that "if Prolia treatment is discontinued, patients should be transitioned to an alternative antiresorptive therapy." The American Association of Clinical Endocrinologists guidelines say the same thing at their highest level of confidence. A joint position statement from bone specialists in the United States and Europe puts a clock on it: the replacement medication should begin six months after the final denosumab injection, which is precisely when that last dose would have worn off (Tsourdi and colleagues, Journal of Clinical Endocrinology & Metabolism, 2020).
Two things I would ask of anyone starting this medication. Book your next injection before you walk out of the office, every single time. And if you and your doctor ever decide to stop, choose and schedule the follow-on medication during that same conversation rather than leaving it for later.
The Other Risks, Kept in Proportion
Prolia carries a boxed warning, which is the strongest warning the FDA issues, for severe low blood calcium in people with advanced kidney disease. The label is specific about who this applies to: people whose kidney filtering rate, a lab value called eGFR, has dropped below 30, including anyone on dialysis. In that group there have been hospitalizations and deaths (FDA drug safety communication, January 2024). If your kidney function is normal, this warning is not really about you. You should still know your most recent kidney number before you start, and you should not treat the calcium and vitamin D as optional.
Two rare bone complications get a great deal of attention, and both deserve honest proportion. Osteonecrosis of the jaw is a failure of healing in the jawbone, usually set off by a tooth extraction or an infection. Across the full ten-year study, thirteen cases occurred among more than 4,500 women. The Bone Health and Osteoporosis Foundation describes the fracture-prevention benefit at osteoporosis doses as far outweighing this risk. Counts like this vary a fair amount from study to study, because they are gathered over different lengths of time and in different groups of people, so a number you see in one of my posts will not always line up tidily with a number in another. What holds up across all of them is that at the doses used for osteoporosis, this is an uncommon event. Have a dental exam before your first dose, keep up with your cleanings, and make sure your dentist knows you are on denosumab.
Atypical femoral fractures, meaning unusual breaks in the thighbone, are rarer still. There was one case in each study group over that same ten-year span. They tend to announce themselves ahead of time with a dull ache in the thigh, hip, or groin for weeks before anything actually breaks, so new pain in that area is worth a phone call rather than a wait-and-see.
Serious infections requiring a hospital stay were somewhat more common on denosumab than on placebo in the pivotal trial, skin infections in particular. If you develop a spreading patch of skin that is red, hot, and tender, get it looked at promptly instead of waiting out a weekend. Milder skin problems including eczema, dermatitis, and rash were also more frequent. The drug should not be used during pregnancy, and low blood calcium has to be corrected before anyone starts it.
Why I Think This Deserves a Yearly Conversation
With bisphosphonates, the usual practice is to reassess after about five years and consider a break. Denosumab has no equivalent milestone. Guidelines are explicit that a drug holiday is not appropriate for this class of medication and that treatment should continue for as long as it remains clinically appropriate. There is no built-in stopping point, which also means there is no built-in moment when someone sits down and reviews the decision with you.
I would create that moment yourself, once a year. Ask whether the balance still favors treatment. Your fracture risk shifts as you get older, and so do your kidney function and your dental situation. New research on long-term safety and on what happens after stopping comes out steadily, and what we understood about this drug ten years ago is not what we understand today. The specialists who wrote that 2020 position statement made a point of saying the case for staying on denosumab long term is favorable for people already on it who remain at high fracture risk, while also urging more caution about starting it in younger patients. That kind of nuance moves with the evidence, and an annual check-in is how you keep up with it.
It is also fair to know that guidelines do not all rank this medication the same way. The American College of Physicians, in its 2023 recommendations, suggests denosumab as a second-line option for postmenopausal women who cannot take a bisphosphonate or who have had side effects from one. Other expert groups weigh it more favorably as a starting choice. Thoughtful specialists genuinely disagree here, and where you land depends on your own fracture risk, your kidney function, and how well you do with the alternatives.
A Note on Biosimilars
Since 2024 the FDA has approved biosimilar versions of denosumab, which are highly similar copies of the original biologic drug. The first of them was designated interchangeable, meaning a pharmacy may substitute it without checking back with the prescriber, depending on the laws in your state (FDA announcement). Several more have followed. If your injection turns up one day under an unfamiliar name, that is very likely what happened. The medication itself is the same, and if your insurance drove the switch it may well cost you less. Worth confirming with your pharmacy so it does not arrive as a surprise.
Questions Worth Bringing to Your Appointment
- What is my current kidney function, and does it change whether this medication is safe for me?
- If we start it, what is the plan for how long I stay on it?
- If I ever need to stop, which medication will I switch to, and exactly how soon after my last dose?
- Whose job is it to make sure my next injection gets scheduled on time, mine or the office's?
- Should I see my dentist before my first dose, and is there any dental work I should get done first?
- How much calcium and vitamin D should I be taking, and will we check my blood calcium?
- Can we put this on the agenda to look at again in a year?
Prolia is a good medication that asks something specific of you in return, which is that you stay connected to care. If you have reliable access to a doctor's office and you are prepared to keep the schedule, the ten-year evidence for what it can do is about as good as anything we have. If your access to care feels uncertain to you, for whatever reason, that is worth saying out loud to your doctor before you start. It is useful information for choosing a medication, not something to be embarrassed about.
And whatever you end up taking, the medication is still one piece of a much larger effort. Weight-bearing exercise, enough protein, adequate calcium and vitamin D, decent sleep, and a hard look at the loose rugs and dim hallways in your house. The drug buys you density and time. What you do with your days is what puts it to use.
For a closer look at the medication family denosumab gets compared with most often, you can read my post on bisphosphonates.